Ignite Creation Date:
2024-10-25 @ 7:55 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06507878
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-07-12
Brief Title:
Global Real World Data in Patients With Advanced Thyroid Cancer on Standard of Care and Specialized Interventions- Registry of Oncologic Outcomes With Testing and Treatment
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Global Real World Data in Patients With Advanced Thyroid Cancer on Standard of Care and Specialized Interventions- Registry of Oncologic Outcomes With Testing and Treatment
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
GRASSROOT
Brief Summary:
The goal of this clinical research study is to learn about the barriers in the real world to accessing treatments for ATC And to learn about how patients with ATC tolerate and respond to the commercially available medications for treatment of this disease outside of a clinical study
Detailed Description:
Primary Objectives
The primary objective of this study is to compare overall survival OS between ATC patients treated at MDA versus outside of MDA using treatment regimens offered at MDA based on BRAF status and stage of the disease We will gather prospective real-world large-scale comprehensive data on these patients who are unable to access traditional clinical trials but are treated with MDA regimens assigned by stage and BRAF-status
Secondary Objectives
1 To evaluate effect of chemotherapy immunotherapy and radiation therapy on the quality of life for ATC survivors
2 To evaluate how factors such as health insurance and lack of coverage adherence and other sociodemographic characteristics influences patient outcomes
The primary objective of this study is to compare overall survival OS between ATC patients treated at MDA versus outside of MDA using treatment regimens offered at MDA based on BRAF status and stage of the disease We will gather prospective real-world large-scale comprehensive data on these patients who are unable to access traditional clinical trials but are treated with MDA regimens assigned by stage and BRAF-status
Secondary Objectives
1 To evaluate effect of chemotherapy immunotherapy and radiation therapy on the quality of life for ATC survivors
2 To evaluate how factors such as health insurance and lack of coverage adherence and other sociodemographic characteristics influences patient outcomes
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None